Formularies are the specific lists of drugs a health plan agrees to pay for, organized into tiers that set the patient's copay or coinsurance. A drug is non-formulary when the plan's Pharmacy and Therapeutics committee left it off that list entirely, typically because a therapeutically equivalent generic, biosimilar, or preferred brand already treats the same condition at lower cost. Non-formulary status is a harder barrier than prior authorization or step therapy, both of which apply to a drug that is already on the formulary but restricted. Every commercial insurer, Medicare Part D sponsor, Medicaid managed care plan, and ACA marketplace insurer publishes its formulary online and updates it at least annually, and federal and state law require each of these payers to offer a formal exception process when a non-formulary drug is medically necessary.
Federal Medicare Part D rules set the clearest national benchmark for how fast a formulary exception must be decided. Under the Medicare Prescription Drug Benefit Manual and 42 CFR Section 423.578, a Part D plan must issue a standard coverage determination within 72 hours and an expedited determination within 24 hours once the prescriber's supporting statement is received, or within 14 calendar days of the original request if no statement arrives. Commercial and ACA marketplace plans generally follow similar timelines under state insurance regulation and the Affordable Care Act's internal claims and appeals rules, though the exact clock varies by state. Medicaid managed care organizations must respond to a prior authorization or formulary exception request within 24 hours under federal Medicaid regulation, with a mandatory 72-hour emergency supply while the review is pending.
Patients often confuse three distinct coverage barriers: non-formulary (the drug is not on the list at all), non-preferred (the drug is on the list but on a higher-cost tier), and prior authorization or step therapy (the drug is on the list but requires extra clinical justification before dispensing). Each barrier has a different fix. A non-formulary denial requires a formal formulary exception request with a letter of medical necessity; a non-preferred tier placement usually cannot be appealed away but the patient can request a tiering exception to pay the lower-tier copay; and a prior authorization denial is resolved by submitting the missing clinical documentation the plan already asked for. Knowing which barrier applies determines which appeal to file, and filing the wrong one wastes the limited appeal window.
What Non-Formulary Drug Coverage Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same non-formulary drug coverage can cost many times more at a hospital than at your local pharmacy:
2026 Non-Formulary Drug Coverage Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, non-formulary, no exception approved) | $15 - $2,500+/month | Full cash price in 2026 while an exception request is pending or before one is filed. A generic-only non-formulary situation may run $15 to $90/month; a specialty brand can run $1,000 to $2,500+/month. |
| Commercial insurance, formulary exception approved | $10 - $150/month | Once approved, the plan typically applies the highest existing formulary tier's cost-sharing (often the specialty tier), not a $0 copay. Confirm the exact tier assignment in the approval letter. |
| Medicare Part D, formulary exception approved (2026) | $0 - $200/month, capped at $2,100/year | The $2,100 annual out-of-pocket cap under the Inflation Reduction Act of 2022 applies once the drug is covered. Approved exceptions are typically placed at the plan's highest cost-sharing tier unless a tiering exception is also granted. |
| Medicaid, non-preferred or excluded drug, exception approved | $0 - $8/prescription | Federal regulation 42 CFR 447.54 caps the copay at nominal amounts once a state Medicaid agency or managed care plan approves a formulary exception for a non-preferred or excluded drug. |
| Manufacturer PAP fallback (exception denied or uninsured) | $0 (free) for eligible patients | Manufacturer patient assistance programs typically cap eligibility at 300% to 400% of the federal poverty level in 2026 for uninsured patients or those with a documented denial for the specific drug. |
Costs shown assume the stated coverage status has been confirmed. Without an approved formulary exception, the retail cash price applies at every payer type. All Medicare figures reflect 2026 Part D benefit design under the Inflation Reduction Act.
Source: CMS Medicare Prescription Drug Benefit Manual Chapter 6, 42 CFR Section 423.578, 42 CFR Section 447.54, GoodRx 2026 pharmacy survey
Why Hospitals Charge So Much
Hospitals rarely bill a separate line-item copay when a non-formulary drug is given during an inpatient stay, because the drug is folded into a bundled facility payment, typically a diagnosis-related-group rate for Medicare and Medicaid or a similar case-rate arrangement for commercial plans. The itemized bill a patient receives after discharge still lists the drug's charge separately, and that charge is frequently marked up several times above the outpatient retail price even though the hospital's actual reimbursement for the drug is bundled into the overall facility payment rather than paid per item. A non-formulary specialty drug administered inpatient can appear on a bill at $1,500 to $6,000 for a single dose, far above what the same drug costs filled at a retail pharmacy.
Three structural factors drive these inflated inpatient line items for non-formulary drugs beyond the outpatient cash price. Facility handling fees get layered onto the drug's wholesale acquisition cost, nursing administration charges apply even when a patient could self-administer the drug once discharged, and revenue-cycle coding sometimes assigns the drug to a higher internal charge tier than its actual formulary status would suggest. Patients who see a non-formulary drug billed at several times its retail cash price should request an itemized bill, confirm the National Drug Code matches the prescription that was actually dispensed, and use the medical bill analyzer to flag the line item for review before paying it.
Patient Assistance Programs
Manufacturer patient assistance programs (PAPs) exist for nearly every branded non-formulary drug and are worth pursuing in two situations: while a formulary exception request is pending, since exceptions can take days to weeks to resolve, and after an exception is denied on final appeal. PAPs generally exclude patients with active Medicaid coverage under federal anti-kickback rules, but they remain available to uninsured patients and, for many manufacturers, to Medicare beneficiaries who do not qualify for the Extra Help low-income subsidy. A written denial letter from the health plan documenting the non-formulary status strengthens a PAP application significantly.
Patient assistance programs for Non-Formulary Drug Coverage| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NeedyMeds Patient Assistance Program Database | Free searchable directory of hundreds of manufacturer PAPs, disease-specific assistance funds, and drug discount cards, organized by drug name and manufacturer | needymeds.org |
| RxAssist Patient Assistance Program Center | Nonprofit-maintained directory listing manufacturer PAP eligibility rules, income thresholds, and application forms by drug and manufacturer | rxassist.org |
| AstraZeneca AZ&Me Prescription Savings Program | Free medication for uninsured patients and Medicare beneficiaries without Extra Help, at income up to 300% FPL for most primary and specialty products in 2026 (500% FPL for rare-disease products) | azandmeapp.com |
| Manufacturer-specific PAPs (examples: Bristol Myers Squibb Patient Assistance Foundation, Lilly Cares Foundation, NovoCare, Pfizer RxPathways, Merck Patient Assistance Program) | Free or reduced-cost drug for uninsured patients, typically at incomes up to 300% to 400% of the federal poverty level; many accept a written formulary-exception denial letter as supporting documentation | manufacturer website |
Manufacturer copay cards and savings cards, sometimes called a manufacturer coupon, cannot be used by anyone with Medicare, Medicaid, TRICARE, or VA coverage under the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). Applying a manufacturer coupon to a government-insured claim is a compliance violation and can trigger a clawback that later shows up as an unexpected charge. If your non-formulary drug is denied and you have Medicare or Medicaid, apply for the income-based manufacturer PAP instead of a copay card.
Source: NeedyMeds.org, RxAssist.org, AstraZeneca AZ&Me (azandmeapp.com), 42 U.S.C. Section 1320a-7b
Medicare Part D
Medicare Part D plans must maintain a formulary exception process for any drug they leave off their covered drug list. Under the Medicare Prescription Drug Benefit Manual Chapter 6 and 42 CFR Section 423.578, the plan must issue a standard coverage determination within 72 hours and an expedited determination within 24 hours once the prescriber submits a supporting statement explaining why formulary alternatives would be ineffective or harmful. If no supporting statement arrives, the clock still starts automatically 14 calendar days after the original request. Beneficiaries or their prescribers submit the request using the plan's Model Coverage Determination Request Form, available on the plan's website or through Medicare.gov.
The 2026 Medicare Part D annual out-of-pocket cap of $2,100, set under the Inflation Reduction Act of 2022, applies once an exception is approved and the drug becomes a covered benefit. Approved non-formulary drugs are typically placed at the plan's highest existing cost-sharing tier, so a beneficiary should also consider requesting a tiering exception if a lower-tier copay is medically justified. The $2,100 cap does not help while the drug remains formally denied, which is why filing the exception request quickly, ideally the same week as the denial, matters more than the annual cap itself.
Part D appeals for a denied formulary exception proceed through five formal levels. Level 1 is the coverage determination itself, decided within 72 hours standard or 24 hours expedited. Level 2 is a redetermination, filed with the plan within 60 days of the Level 1 denial and decided within 7 days. Level 3 is an Independent Review Entity review, automatic if Level 2 is denied and the plan does not act within its timeframe. Level 4 is the Office of Medicare Hearings and Appeals, available when the drug's value exceeds a minimum threshold that CMS updates annually. Level 5 is Medicare Appeals Council review, followed by federal district court. Most non-formulary Part D disputes resolve at Level 1 or Level 2 when the prescriber's supporting statement is thorough.
Common Non-Formulary Drug Coverage Billing Errors
These are the most common billing and coverage errors that complicate a non-formulary drug denial in 2026. Checking for them before paying a pharmacy bill or accepting a denial can save significant money:
- Pharmacy processes the claim as cash-pay instead of attempting the formulary exception override the plan already approved. If a pharmacy charges full retail price after an exception was granted, ask the pharmacy to reprocess the claim using the plan's authorization number.
- Manufacturer coupon or savings card applied to a Medicare or Medicaid claim in error. Federal anti-kickback rules bar manufacturer coupons from supplementing government-insured cost-sharing; if one was applied, the pharmacy may face a clawback that later appears as an unexpected patient charge.
- 72-hour emergency supply not provided while a Medicaid formulary exception is pending. Federal regulation requires pharmacies to dispense at least a 72-hour emergency supply when a decision has not been made in time; refusal is a compliance violation worth reporting to the state Medicaid agency.
- Approved exception billed at the wrong formulary tier. An approved non-formulary exception should carry the copay of the plan's highest existing tier, not the full retail price and not automatically the lowest tier. Compare the explanation of benefits against the approval letter's stated tier assignment.
- Appeal filed past the deadline. Medicare Part D gives 60 days from a Level 1 denial to file a Level 2 redetermination; commercial and marketplace plans typically give 30 to 180 days, stated on the denial letter. Missing the window forfeits appeal rights for that coverage period.
- Balance-billed above the Medicaid- or Medicare-allowed rate after an exception is approved. Federal law prohibits providers from balance-billing Medicaid beneficiaries above the allowed rate, and Medicare has similar limiting-charge protections; a surprise bill for the difference should be disputed directly with the plan.
Frequently Asked Questions
Is there a generic or biosimilar alternative when my drug is non-formulary?
Often yes. Plans typically exclude a specific brand from the formulary precisely because an FDA AB-rated generic or an FDA-interchangeable biosimilar already treats the same condition at lower cost. Ask your pharmacist whether that alternative already sits on your formulary; switching is usually covered immediately at a low copay without any exception process. When no generic or biosimilar exists for the drug you need, the formulary exception route is the only path to coverage.
How do I apply for a manufacturer patient assistance program if my drug is non-formulary?
Search needymeds.org or rxassist.org by the drug name to find the manufacturer's PAP. Complete the patient and prescriber sections of the application, gather proof of income and US residency, your prescription, and your plan's written non-formulary denial letter, then submit by fax, mail, or the manufacturer's online portal. Most PAPs cap eligibility at 300% to 400% of the federal poverty level in 2026 and process applications within 7 to 21 business days.
Can I use a manufacturer savings card if my non-formulary drug is denied and I have Medicare?
No. Federal anti-kickback law (42 U.S.C. Section 1320a-7b) prohibits anyone with Medicare, Medicaid, TRICARE, or VA coverage from using a manufacturer copay card or manufacturer coupon. These cards are for commercially insured or uninsured patients only. If you have Medicare or Medicaid and your non-formulary drug is denied, apply for the manufacturer's income-based patient assistance program instead, which does not violate anti-kickback rules.
What if my insurance denies coverage because the drug is non-formulary?
Request the written denial notice, then have your prescriber file a formal formulary exception request with a letter of medical necessity documenting why formulary alternatives would be ineffective or harmful. Medicare Part D plans must decide within 72 hours standard or 24 hours expedited. If denied, file an internal appeal within the stated deadline, then escalate to independent external review, which is binding on the plan.
Does the IRA's Maximum Fair Price help with a non-formulary drug?
Only indirectly and only for the 10 drugs Medicare has negotiated so far. The Inflation Reduction Act's Maximum Fair Price applies to Medicare Part B and Part D pricing for those specific drugs starting January 1, 2026, but it does not force a plan to add a drug to its formulary. A drug can have a negotiated Maximum Fair Price and still require a formulary exception if a specific Part D plan has excluded it, though most Round-1 negotiated drugs are widely covered because of their high utilization.
What does a non-formulary drug cost without insurance at the pharmacy counter?
It depends heavily on which drug is involved. A non-formulary situation involving a brand with a cheap generic alternative, like brand Crestor versus generic rosuvastatin, can mean paying $280 to $400 a month for the brand in 2026 versus $2 to $20 for the covered generic. A non-formulary specialty biologic without a lower-cost alternative can run $1,000 to $2,500 or more per month in cash.
Do I qualify for a manufacturer patient assistance program while I wait on a formulary exception?
Often yes, if you are uninsured or your denial letter documents that the drug is not covered. Most manufacturer PAPs, such as AstraZeneca's AZ&Me program, accept applications from patients with income up to 300% to 400% of the federal poverty level in 2026, and a written non-formulary denial letter strengthens the application while the exception appeal is still pending.
What is the difference between a non-formulary drug, a non-preferred drug, and one that needs prior authorization?
Non-formulary means the drug is not on the plan's covered list at all and requires a formulary exception. Non-preferred means the drug is on the list but sits on a higher-cost tier, addressed with a tiering exception rather than a full exception. Prior authorization or step therapy means the drug is on the list and will be covered once you submit the specific clinical documentation the plan requires. Each barrier needs a different type of request, so confirm which one applies before filing an appeal.
